ACP
TRML

Altitude Crest Partners’s Tourmaline Bio TRML Stock Holding History

Altitude Crest Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47,400
Closed -$1.09M – 27
2024
Q1 		$1.09M Buy
+47,400
New +$1.67M 0.46% 28

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Altitude Crest Partners's TRML Position: Q2 2024 in Review

Altitude Crest Partners sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 47,400 shares — an estimated $1.09M sold.

Altitude Crest Partners first reported a position in TRML in Q1 2024 and held it in 1 quarter. The position peaked at $1.09M in Q1 2024. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Altitude Crest Partners reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 47,400 Tourmaline Bio shares in Q2 2024, an estimated $1.09M.
  • Altitude Crest Partners first reported a position in Tourmaline Bio in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Tourmaline Bio position peaked at $1.09M in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.